SARTORIUS-AG
The Sartorius Group sold its Industrial Technologies Division with economic effect as of January 1, 2015. Therefore, Sartorius Group reporting for the full year of 2014 was already based on continuing operations according to the IFRS International Financial Reporting Standards (see the 2014 Annual Report). In addition to the disclosures made in the annual report, the following supplementary information is provided on business development at the Group and division levels for the regular reporting periods up to and including the full year of 2014 for better comparison with reported future quarterly results:
| Sartorius Group | ||||||||
| in millions of €, unless otherwise specified | ||||||||
| 3M 2014 | 6M 2014 | 9M 2014 | FY 2014 | |||||
| Order intake | 225.1 | 440.5 | 658.1 | 929.2 | ||||
| Sales revenue | 203.1 | 423.0 | 645.5 | 891.2 | ||||
| Cost of sales | -105.1 | -218.6 | -333.3 | -461.6 | ||||
| Gross profit on sales | 98.0 | 204.4 | 312.2 | 429.6 | ||||
| Selling and distribution costs | -48.7 | -98.3 | -147.2 | -200.2 | ||||
| Research and development expenses | -13.4 | -25.3 | -38.2 | -50.4 | ||||
| General administrative expenses | -14.1 | -27.9 | -41.9 | -58.3 | ||||
| Other operating income | expenses | 3.4 | 5.1 | 5.2 | 5.5 | ||||
| Earnings before interest and taxes (EBIT) | 25.2 | 58.0 | 90.2 | 126.2 | ||||
| Financial result | -4.4 | -10.0 | -16.3 | -29.9 | ||||
| Profit before tax | 20.8 | 48.0 | 73.9 | 96.3 | ||||
| Income taxes | -6.3 | -17.5 | -25.1 | -32.4 | ||||
| Profit after tax from continuing operations | 14.6 | 30.5 | 48.7 | 63.9 | ||||
| Profit after tax from discontinued operation | 0.5 | 1.6 | 3.4 | 4.5 | ||||
| Net profit for the period | 15.1 | 32.1 | 52.1 | 68.4 | ||||
| Attributable to: | ||||||||
| Equity holders of Sartorius AG | 11,0 | 23.1 | 37.8 | 48.5 | ||||
| Non-controlling interest | 4.0 | 9.0 | 14.3 | 19.9 | ||||
| Reconciliation to Underlying EBITDA | ||||||||
| Extraordinary items | 1.2 | 2.0 | 4.0 | 8.3 | ||||
| Amortization | depreciation | 12.2 | 24.8 | 37.8 | 52.3 | ||||
| Underlying EBITDA1) | 38.7 | 84.8 | 131.9 | 186.8 | ||||
| Underlying EBITA margin in %1) | 19.0 | 20.1 | 20.4 | 21.0 | ||||
| Sartorius Divisions | ||||||||
| € in millions, unless otherwise specified | ||||||||
| 3M 2014 | 6M 2014 | 9M 2014 | FY 2014 | |||||
| Bioprocess Solutions | ||||||||
| Order intake | 158.1 | 304.9 | 460.3 | 652.7 | ||||
| Sales revenue | 137.7 | 291.1 | 444.7 | 615.6 | ||||
| Underlying EBITDA1) | 29.6 | 66.4 | 103.0 | 145.6 | ||||
| Underlying EBITDA margin in %1) | 21.5 | 22.8 | 23.2 | 23.7 | ||||
| Lab Products & Services | ||||||||
| Order intake | 67.0 | 135.7 | 197.8 | 276.5 | ||||
| Sales revenue | 65.4 | 131.9 | 200.8 | 275.5 | ||||
| Underlying EBITDA1) | 9.1 | 18.4 | 29.0 | 41.2 | ||||
| Underlying EBITDA margin in %1) | 13.9 | 14.0 | 14.4 | 15.0 | ||||
| Reconciliation to the Relevant Net Profit | ||||||||
| in millions of €, unless otherwise specified | ||||||||
| 3M 2014 | 6M 2014 | 9M 2014 | FY 2014 | |||||
| Earnings before interest and taxes (EBIT) | 25.2 | 58.0 | 90.2 | 126.2 | ||||
| Extraordinary items | 1.2 | 2.0 | 4.0 | 8.3 | ||||
| Amortization | 3.5 | 7.0 | 10.6 | 14.0 | ||||
| Normalized financial result2) | -4.3 | -10.0 | -14.4 | -20.2 | ||||
| Normalized income tax3) | -7.7 | -17.1 | -27.1 | -38.5 | ||||
| Underlying earnings after taxes | 17.9 | 39.9 | 63.3 | 89.8 | ||||
| Non-controlling interest | -4.7 | -10.6 | -16.6 | -23.7 | ||||
| Underlying earnings after taxes and non-controlling interest | 13.3 | 29.3 | 46.6 | 66.1 | ||||
| per ordinary share (in €) | 0.77 | 1.71 | 2.72 | 3.87 | ||||
| per preference share (in €) | 0.79 | 1.73 | 2.74 | 3.89 | ||||
| Relevant net profit after non-controlling interest4) | 13.8 | 31.3 | 50.5 | 73.7 | ||||
| per ordinary share (in €) | 0.80 | 1.82 | 2.96 | 4.31 | ||||
| per preference share (in €) | 0.82 | 1.84 | 2.98 | 4.33 | ||||
|
1) Adjusted for extraordinary items |
||||||||
|
2) Financial result excluding fair value adjustments of hedging instruments and non-periodic expenses and income |
||||||||
|
3) Underlying income tax, based on the underlying profit before taxes and non-cash amortization |
||||||||
|
4) Including discontinued operation |
||||||||
A Profile of Sartorius
The Sartorius Group is a leading international pharmaceutical and laboratory equipment provider covering the two segments of Bioprocess Solutions and Lab Products & Services. In 2014, the technology group earned sales revenue of 891.2 million euros. Founded in 1870, the Goettingen-based company currently employs more than 5,500 persons. The major areas of activity of its Bioprocess Solutions segment cover filtration, fluid management, fermentation, cell cultivation and purification, and focus on production processes in the biopharmaceutical industry. The Lab Products & Services segment primarily manufactures laboratory instruments and lab consumables. Sartorius has its own production facilities in Europe, Asia and America as well as sales subsidiaries and local commercial agencies in more than 110 countries.
Contact:
Sartorius AG
Petra Kirchhoff, +49 (0)551-308-1686
Vice
President of Group Communications and IR
petra.kirchhoff@sartorius.com
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Rimini Street Announces Upcoming 2025 Investor Conference Schedule15.5.2025 22:51:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced that Michael L. Perica, chief financial officer, and Dean Pohl, vice president, treasurer and investor relations, will be presenting and meeting with investors one-on-one and in small group meetings at the following conferences: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515374696/en/ Rimini Street Announces Upcoming 2025 Investor Conference Schedule May 28, 2025: Craig-Hallum 22nd Annual Institutional Investor Conference, Minneapolis May 29, 2025: TD Cowen 53rd Annual TMT Conference, New York City Fireside Chat: 1:15 pm Eastern, webcast link June 24-26, 2025: Roth 15th Annual London Conference, London To schedule a meeting please contact your salesperson or Rimini Street Investor Relations at IR@rimin
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States15.5.2025 20:30:00 CEST | Press release
Zynyz® (retifanlimab-dlwr), a PD-1 inhibitor, is now approved for the treatment of advanced squamous cell carcinoma of the anal canal (SCAC) in combination with chemotherapy and as a monotherapyPatients with SCAC treated with Zynyz achieved a statistically significant improvement in progression-free survival and improvement in overall survival Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz® (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). In addition, the FDA granted approval for Zynyz as a single agent for the treatment of adult patients with locally recurrent or with metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy. Thi
DDC Announces Record 2024 Growth and Strategic Bitcoin Reserve Initiative in Shareholder Letter by Founder & CEO Norma Chu15.5.2025 20:23:00 CEST | Press release
DDC Enterprise Ltd. (NYSEAM: DDC), today released its 2024 full year results alongside a Shareholder Letter from Founder, Chairwoman, and CEO Norma Chu, underscoring the company’s positive financial performance and unveiling a pioneering Bitcoin accumulation strategy poised to redefine long-term value creation. To Our Valued Shareholders, 2024 was a year of transformative growth and strategic milestones for DDC. I am thrilled to share that we not only met our financial forecasts but exceeded expectations, delivering strong performance across key metrics while laying the groundwork for an even more exciting future. As we enter 2025, our momentum is accelerating, driven by disciplined execution and a bold new chapter in our corporate strategy. 2024 Financial & Operational HighlightsRevenue Growth: USD 37.4 million, a 33% year-over-year increase, propelled by the strategic acquisition of U.S. brands and sustained resilience in our core China operations. Margin Expansion: Gross profit marg
Ras Al Khaimah’s Strong Economic and Investment Environment Validated by Fitch Affirmation of ‘A+’ Credit Rating, With Stable Outlook15.5.2025 20:18:00 CEST | Press release
The positive rating reflects the Emirate’s strong long-term growth prospects and ongoing economic diversification Ras Al Khaimah’s strategic approach to sustainable, cross-sector growth and strong economic and investment environment has been validated by international credit rating agency Fitch, which reaffirmed the rating at ‘A+’ with a stable outlook. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515907689/en/ Ras Al Khaimah’s strong economic and investment environment validated by Fitch affirmation of ‘A+’ credit rating, with Stable Outlook (Photo: AETOSWire) Ras Al Khaimah Government welcomed the announcement as an endorsement of the Emirate’s resilient and expanding economy, sound fiscal management and the clear vision and unwavering commitment of its leadership to sustainable, long-term development and growth. The Emirate’s landmark tourism projects, including a major integrated resort, luxury hotels and world-clas
Cessna Citation CJ4 Gen3 Flight Test Program Advances Through Milestones as Second Test Article Takes Flight15.5.2025 20:00:00 CEST | Press release
Textron Aviation today announced a major program milestone for the Cessna Citation CJ4 Gen3 flight test program with the successful first flight of a second test article — P1. Testing on the P1 aircraft will focus on avionics, human factors and interiors. The Citation CJ4 Gen3 business jet is designed to keep pilots a step ahead in the cockpit by offering the next-generation Garmin G3000 PRIME avionics along with the most standard features in its class. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515438856/en/ Cessna Citation CJ4 Gen3 flight test program advances through milestones as second test article takes flight. (Photo Credit: Textron Aviation) The Cessna Citation CJ4 Gen3 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. “This achievement continues the forward momentum of the CJ4 Gen3 program and reflects the dedication and expertise of our team in designing, certifying an
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum